Kite Pharma’s CAR T-Cell Treatment Approved, Cheaper Than Tisagenlecleucel – AJMC.com Managed Markets Network
|
Kite Pharma's CAR T-Cell Treatment Approved, Cheaper Than Tisagenlecleucel
AJMC.com Managed Markets Network The FDA has given the go-ahead for a second chimeric antigen receptor (CAR) T cell therapy: axicabtagene ciloleucel (Yescarta), developed by Kite Pharma, which was recently acquired by Gilead Sciences, has been approved to treat adult patients with … |
